1h Free Analyst Time
The menstrual drugs market is forecasted to grow by USD 3.61 billion during 2023-2028, accelerating at a CAGR of 7.75% during the forecast period. The report on the menstrual drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing emphasis on educating women about menstrual health, rising prevalence of menstrual disorders, and economic growth and rising disposable incomes.
The menstrual drugs market is segmented as below:
By Type
- Hormonal treatments
- Pain relief medications
- PMS and PMDD medications
- Menstrual regulation drugs
- Endometriosis treatments
By Route Of Administration
- Oral medications
- Injectables
- Topical applications
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the menstrual drugs market covers the following areas:
- Menstrual drugs market sizing
- Menstrual drugs market forecast
- Menstrual drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Route of Administration
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the menstrual drugs market: AbbVie Inc., Adorefem, Bayer AG, Cipla Inc., DR Reddys Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Himalaya Wellness Co., Johnson and Johnson Services Inc., Leeford Healthcare Ltd., Mallinckrodt PLC, Maxwellia Ltd., Perrigo Co. PLC, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi SA, SteriMax Inc., Sumitomo Chemical Co. Ltd., Teva Pharmaceutical Industries Ltd., Walgreens Boots Alliance Inc., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in popularity of drug therapy."
According to the report, one of the major drivers for this market is the growing emphasis on educating women about menstrual health.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Adorefem
- Bayer AG
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- GlaxoSmithKline Plc
- Haleon Plc
- Himalaya Wellness Co.
- Johnson and Johnson Services Inc.
- Leeford Healthcare Ltd.
- Mallinckrodt Plc
- Maxwellia Ltd.
- Perrigo Co. Plc
- Pfizer Inc.
- Reckitt Benckiser Group Plc
- Sanofi SA
- SteriMax Inc.
- Sumitomo Chemical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Walgreens Boots Alliance Inc.
- Zydus Lifesciences Ltd.
